Clinical Trial Update: A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines [Phase 3]

View source ↗

Summary

A Phase III clinical trial assessing safety and efficacy of ligelizumab for chronic spontaneous urticaria in adolescents and adults inadequately controlled with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ligelizumab (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2022-12-30